@article{3e757c9b2635469ba8b87bca92dd1241,
title = "Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS",
abstract = "AIM: To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR-P): the Structured Interview for Psychosis-risk Syndromes (SIPS) and the Comprehensive Assessment of At-Risk Mental States (CAARMS).METHODS: The initial workshop is described in the companion report from Addington et al. After the workshop, lead experts for each instrument continued harmonizing attenuated positive symptoms and criteria for psychosis and CHR-P through an intensive series of joint videoconferences.RESULTS: Full harmonization was achieved for attenuated positive symptom ratings and psychosis criteria, and modest harmonization for CHR-P criteria. The semi-structured interview, named Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS), generates CHR-P criteria and severity scores for both CAARMS and SIPS.CONCLUSIONS: Using the PSYCHS for CHR-P ascertainment, conversion determination, and attenuated positive symptom severity rating will help in comparing findings across studies and in meta-analyses.",
keywords = "ascertainment, clinical high risk, early detection, psychometrics, severity rating",
author = "Woods, \{Scott W\} and Sophie Parker and Kerr, \{Melissa J\} and Walsh, \{Barbara C\} and Wijtenburg, \{S Andrea\} and Nicholas Prunier and Nunez, \{Angela R\} and Kate Buccilli and Catalina Mourgues-Codern and Kali Brummitt and Kinney, \{Kyle S\} and Carli Trankler and Julia Szacilo and Beau-Luke Colton and Munaza Ali and Anastasia Haidar and Tashrif Billah and Kevin Huynh and Uzair Ahmed and Adery, \{Laura L\} and Marcy, \{Patricia J\} and Kelly Allott and Paul Amminger and Celso Arango and Broome, \{Matthew R\} and Cadenhead, \{Kristin S\} and Chen, \{Eric Y H\} and Jimmy Choi and Philippe Conus and Cornblatt, \{Barbara A\} and Glenth{\o}j, \{Louise Birkedal\} and Horton, \{Leslie E\} and Joseph Kambeitz and Tina Kapur and Keshavan, \{Matcheri S\} and Nikolaos Koutsouleris and Kerstin Langbein and Suzie Lavoie and Diaz-Caneja, \{Covadonga Martinez\} and Mathalon, \{Daniel H\} and Mittal, \{Vijay A\} and Merete Nordentoft and Ofer Pasternak and Pearlson, \{Godfrey D\} and Gaspar, \{Pablo A\} and Shah, \{Jai L\} and Stefan Smesny and Stone, \{William S\} and Strauss, \{Gregory P\} and Kahn, \{Rene S\}",
note = "Funding Information: The Accelerating Medicines Partnership Schizophrenia (AMP SCZ) is a public‐private partnership managed by the Foundation for the National Institutes of Health. The AMP SCZ research program is supported by contributions from the AMP SCZ public and private partners, including NIMH (U24MH124629, U01MH124631, and U01MH124639) and Wellcome (220664/Z/20/Z and 220664/A/20/Z). AMP SCZ Steering Committee members include: R. Benabou, L. Bilsland, L.S. Brady, T. Brister, F. Butlen‐Ducuing, K. Duckworth, G.K. Farber, T.R. Farchione, B.A. Fischer, S. Frangou, S.T. Garcia, N. Gogtay, J.A. Gordon, R.K. Heinssen, W. Horton, B.R. Johnson, P.S. Joshi, C.A. Larrauri, S.H. Lisanby, G. Pandina, S.E. Roth, M. Sand, V.M. Sharma, B. Staglin, A. Travaglia, E. Velhorst, G. Wunderlich. Other AMP SCZ members not listed elsewhere include: M. Grabb, M. Hillefors, D. Janes, S.E. Morris, J. Pevsner. Funding Information: S.W.W. has received sponsor‐initiated research funding support from Boehringer‐Ingelheim, Amarex, and SyneuRx. He has been a paid consultant to Boehringer‐Ingelheim, New England Research Institute, and Takeda. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. B.C.W. has been a paid consultant with Boehringer‐Ingelheim and the Pier Institute. A.A. holds equity and is a member of the Technology Advisory Board for Neumora Therapeutics, Inc.; is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019. J.M.K has received honoraria for lectures or consulting from Alkermes. R.S.K. has consulted for Alkermes, Otsuka, and Sunovion. D.O.P reports consulting for Alkermes. S.R.C. reports Speaker's Fees / Honoraria: Janssen‐Cillag Australia, Lundbeck‐Otsuka Australia, Servier Australia Advisory Board: Lundbeck – Otsuka Australia (Maintena, Brexpiprazole) Investigator initiated grants: Janssen‐Cillag Australia, Lundbeck‐Otsuka AustraliaTravel Support: Janssen‐Cillag Australia. D.H.M. has served as a consultant for Neurocrine Biosciences. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. E.Y.H.C. reports investigator initiated grants: Janssen‐Cillag. C.M.D‐C. reports grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024) and honoraria from Exeltis and Angelini. P.J.M. has received sponsor initiated funding from Alkermes, Boehringer Ingelheim, Roche, NeuroRX, and Otsuka and honorarium from Alkermes, Lundbeck, Otsuka, and BioXcel. Other authors report no conflict of interest. Publisher Copyright: {\textcopyright} 2023 The Authors. Early Intervention in Psychiatry published by John Wiley \& Sons Australia, Ltd.",
year = "2024",
month = apr,
doi = "10.1111/eip.13457",
language = "English",
volume = "18",
pages = "255--272",
journal = "Early Intervention in Psychiatry",
issn = "1751-7885",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}